2015 Kicked Off in Style for the CDx Industry

Attendance doubled in 2015 to welcome more that 75 leading CDx organisations to share valuable clinical and commercial insight into the co-development of drug-CDx combinations, including Pfizer, Novartis, Bayer, Merck, Boehringer Ingelheim, Sanofi to name a few.

There are possibly too many highlights from World CDx 2015, but here are a few talks that got rave reviews:

  • Abderrahim Mahfoudi, Senior Director of Scientific Partnerships & Coordination at Sanofi discussed the factors to consider when selecting the right diagnostic partner from Sanofi’s point of view.
  • Klaus Lindpainter, Chief Scientific Officer at Thermo Fisher Scientific kicked off World CDx Berlin 2015 presenting on a unified approach to NGS-based oncology companion diagnostic development.
  • Maria Orr, Executive Director, Personalised Healthcare & Biomarkers at AstraZeneca discussed the lesson’s learnt from late-phase oncology clinical trials at AstraZeneca.
  • Richard Buller, VP, Oncology Clinical Development, at Pfizer, Mark Roberts, Director, Diagnostic Development at Covance, Hans Johansson, VP, Companion Diagnostics at Thermo Fisher Scientific, and Joachim Reischl Head of Global Biomarkers at Bayer joined chairman David Jackson, VP, Companion Diagnostics at Arno Therapeutics for the keynote interview session to discuss the biggest challenges and opportunities with companion diagnostics.

Rest assured World CDx Europe will be back bigger and better than ever in order to drive forward CDx collaborations between senior level pharma, biotech, diagnostic, technology & CRO stakeholders. 

Featured Speakers from 2015:

  • Joachim ReischlHead, Global Biomarker Strategy & Development Bayer

  • Richard BullerVice President, Oncology Clinical Development Pfizer

  • Maria OrrExecutive Director, Personalised Healthcare & Biomarkers AstraZeneca

  • Klaus LindpaintnerChief Scientific Officer Thermo Fisher Scientific